Designer immune cells take on rare sarcomas
NCT ID NCT05993299
First seen Mar 18, 2026 · Last updated Jun 23, 2026 · Updated 25 times
Summary
This phase 2 trial tests a personalized cell therapy called Lete-Cel in 7 people with advanced synovial sarcoma or myxoid/round cell liposarcoma that has not been treated before. Participants receive their own immune cells that have been engineered to recognize and attack their cancer, along with chemotherapy to prepare the body. The main goal is to see if the tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU de Bordeaux GH Sud Hôpital Haut Lévêque
Pessac, 33604, France
-
CIUSSS de L'Est-De-Lile-De-Montreal
Montreal, Quebec, H1T 2M4, Canada
-
Centre Léon Bérard
Lyon, 69373, France
-
Christie Hospital NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02114, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Fondazione IRCCS Instituto Nazionale Dei Tumori
Milan, 20133, Italy
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109-1024, United States
-
Froedtert Hospital
Milwaukee, Wisconsin, 53226, United States
-
Hospital Santa Creu Y Sant Pau
Barcelona, 08025, Spain
-
Hospital Universitario Fundación Jiménez Díaz
Madrid, 28040, Spain
-
Hospital Virgen Del Rocio
Seville, 41013, Spain
-
Ico Duran y Reynals l'Hospitalet de Llobrega
Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Ircss Istituto Clinico Humanitas
Romano di Lombardia, 20089, Italy
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering cancer center
New York, New York, 10065, United States
-
Minnesota Oncology Hematology
Minneapolis, Minnesota, 55455, United States
-
Ohio State University-Columbus
Columbus, Ohio, 43210, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Princess Margaret Cancer Centre
Toronto, M5G 2M9, Canada
-
Royal Marsden Hospital
London, SW3 6JJ, United Kingdom
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Stanford Hospital and Clinics
Stanford, California, 94305, United States
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
The Netherlands Cancer Institute
Amsterdam, 1066 CX, Netherlands
-
University College Hospital-London
London, WC1E 6AG, United Kingdom
-
University Of Texas Southwestern Medical Center
Dallas, Texas, 75390-8565, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Iowa College of Medicine
Iowa City, Iowa, 52242-1009, United States
-
University of Michigan Medical Center
Ann Arbor, Michigan, 48109, United States
-
University of Pittsburgh, Hillman Cancer centre
Pittsburgh, Pennsylvania, 15232, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390-9063, United States
-
University of Utah
Salt Lake City, Utah, 84112, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States
-
Washington University
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Letetresgene autoleucel (engineered immune cells) given with chemotherapy drugs cyclophosphamide and fludarabine
What this could lead to
If it works, this could offer a new treatment option for people with certain advanced sarcomas that have few other choices.
What could go wrong
This is a very small, early-phase trial with only 7 participants. The therapy may not shrink tumors or could cause serious side effects from the chemotherapy or cell infusion.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.